Prostate Cancer Market Gaining Revolution Speeding Up - In Global Eyes

HTF Market Intelligence released a new research report of 212 pages on title 'Prostate Cancer: Global Drug Forecast and Market Analysis to 2028' with detailed analysis, forecast and strategies. The study covers key regions that includes North America, South America, and important players such as Astellas ,AstraZeneca, Bayer, Clovis Oncology, Dendreon, Endo Pharmaceuticals, Endocyte, Ferring Pharmaceuticals, Genzyme, GlaxoSmithKline, Hinova

Request a sample report @ https://www.htfmarketreport.com/sample-report/2257072-prostate-cancer-1

Summary
Prostate Cancer: Global Drug Forecast and Market Analysis to 2028
The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone na�ve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Until recently, the hormone sensitive setting has been dominated by the use of cheaper first-generation hormonal agents, with the use of premium-priced second-generation hormonal agents (Xtandi and Zytiga) limited to metastatic CRPC. The prostate cancer competitive landscape is experiencing a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarker-driven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm.

Key Highlights

- The main driver of the growth of the prostate cancer market will be the continued uptake of second-generation hormonal agents into mHNPC and nmCRPC, where the extended treatment duration will drive overall sales. The second strongest driver will be the increasing number of incident cases.
- To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate greater efficacy (overall survival) compared with available agents. For this reason, agents positioned as first-line mCRPC treatments are being investigated in combination with second-generation hormonal agents, the current standard of care (SOC), to limit the "standard-of-care hurdle". The earlier use of these agents in the hormone-sensitive disease may negatively affect the uptake of this combination in the later line of treatment, mCRPC.
- Due to concerns related to the high annual cost of therapy, GlobalData expects heavy generic erosion of Zytiga when abiraterone generics launch, starting in 2018.

Scope

- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=2257072

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned in the Report

AbbVie
Advanced Accelerator Applications
Advantagene
Allergan
Astellas
AstraZeneca
Bayer
Clovis Oncology
Dendreon
Endo Pharmaceuticals
Endocyte
Ferring Pharmaceuticals
Genzyme
GlaxoSmithKline
Hinova
Ipsen
Janssen/J&J
Merck & Co.
Myovant Sciences
Novartis
Orion
Pfizer
Roche
Sanofi
Sotio
Takeda
TerSera Therapeutics
Tesaro
Tolmar

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/2257072-prostate-cancer-1

Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Prostate Cancer: Executive Summary
2.1 Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
2.2 Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC
2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine
2.5 What Do the Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods, Population
5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer
5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category
5.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis
5.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
5.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status
5.5 Epidemiological Forecast for Prostate Cancer (2018-2028)
5.5.1 Diagnosed Incident Cases of Prostate Cancer
5.5.2 Age-Specific Incident Cases of Prostate Cancer
5.5.3 Diagnosed Incident Cases of P

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/2257072-prostate-cancer-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA - 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at LinkedIn | Facebook | Twitter

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the "Accurate Forecast" in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their "Goals & Objectives".

This release was published on openPR.